Evolution of the Research Literature and the Scientific Community of Alzheimer’s Disease from 1983-2017: A 35-Year Survey.

This study surveys the development of Alzheimer’s disease (AD) in the research literature, the scientific community, and journals containing the letters AD over a period of 35 years. research papers about AD 1983-2017 published in journals indexed in the Web of Science analyzed in seven five-year period.

Total paper AD increased from 1,095 in 1983-1987 to 50 532 by 2013 to 2017 and in the same time period, the number of participating countries went from 27 to 152. The US is the most productive country in the whole, followed by some European countries, Canada, Australia, and Japan. Asian countries have emerged and by 2013-2017, China surpassed all but the US in productivity. Countries in Latin America and Africa have also contributed to the study of AD.

In addition, several non-governmental organizations a new one (for example, ADNI, ADI) has emerged and now plays a key role in the fight against AD. Likewise, publishing scientific AD Universe is expanding in many aspects: the increase in the number of journals that contain the AD paper (227 journals in 1983-1987 to 3257 in 2013-2017); the appearance of several journals AD-focused, for example, Alzheimer’s & Dementia, the Journal of Alzheimer’s; and the development of special issues dedicated to AD. Our paper complements a range of papers that still exist in the theoretical and clinical aspects of AD and provide an overview of the research landscape of the country and contributes journal papers related to AD.


We sought to examine the association of race / ethnicity with a willingness to engage in a study involving a typical procedure of Alzheimer’s disease (AD) clinical trials and determine whether the observed differences can be explained by attitudes.We research studied 2749 adults aged ≥50 years who were enrolled in recruitment registry.

Compared to community-based non-Hispanic (NH) white (n = 2393, 87%), Hispanic (n = 191, 7%), NH Asia (n = 129, 5%) and NH blacks (n = 36 , 1%) was 44%, 46%, and 64% less willing, respectively, contacted for the study who had the typical requirements of AD prevention trials, namely: cognitive testing, brain imaging, blood draws, and studied medicine. Mediation by the attitude of research explored, but it does not explain the observed findings indicate that ethnoracial differences.Our minorities less willing to engage in the study were typical of AD prevention trials. Future work should focus on understanding the factors that drive these differences.

 Evolution of the Research Literature and the Scientific Community of Alzheimer's Disease from 1983-2017: A 35-Year Survey.
Evolution of the Research Literature and the Scientific Community of Alzheimer’s Disease from 1983-2017: A 35-Year Survey.

Photobiomodulation for Alzheimer’s Disease: Translating Basic Research in Clinical Applications.

One of the challenges in translating new therapeutic approaches for bedside patient lies in bridging the gap between laboratory scientists conducting basic research and medical practitioners who are not exposed to highly specialized journals.

This review covers the literature on photobiomodulation therapy as a new approach to prevent and treat Alzheimer’s disease, which aims to bridge the gap that by gathering together the requirements and technical specifications into a single brief advice to the treatment protocol. Given the predicted doubling the number of people affected by dementia and Alzheimer’s disease in the next 30 years, treatment options have shown promising results in studies of cell cultures and animal models, and has been proven safe in humans, should not be left in the dark.

Thalamus (Alzheimer's Disease) Lysate

XBL-10310 0.1 mg
EUR 796.2
Description: Human thalamus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human thalamus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the thalamus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The thalamus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Paraffin Tissue Section - Alzheimers Disease: Brain: Thalamus

T2236079Alz 5 slides
EUR 238

cDNA - Alzheimer's Disease: Brain

C1236035Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Pons

C1236071Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Amygdala

C1236036Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Cerebellum

C1236039Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Hippocampus

C1236052Alz 40 reactions
EUR 886

cDNA - Alzheimer's Disease: Brain: Frontal Lobe

C1236051Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Parietal Lobe

C1236066Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Temporal Lobe

C1236078Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Occipital Lobe

C1236062Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Precentral Gyrus

C1236073Alz 40 reactions
EUR 729

cDNA - Alzheimer's Disease: Brain: Postcentral Gyrus

C1236072Alz 40 reactions
EUR 729

Total RNA - Alzheimer's Disease: Brain

R1236035Alz-50 50 ug
EUR 421.2

Total Protein - Alzheimer's Disease: Brain

P1236035Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Pons

P1236071Alz 1 mg
EUR 471

Frozen Tissue Section - Alzheimer's Disease: Brain

T1236035Alz 5 slides
EUR 475

Total Protein - Alzheimer's Disease: Brain: Amygdala

P1236036Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Cerebellum

P1236039Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Hippocampus

P1236052Alz 1 mg
EUR 580

Total Protein - Alzheimer's Disease: Brain: Frontal Lobe

P1236051Alz 1 mg
EUR 471

Frozen Tissue Section - Alzheimer's Disease: Brain: Pons

T1236071Alz 5 slides
EUR 475

Total Protein - Alzheimer's Disease: Brain: Parietal Lobe

P1236066Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Temporal Lobe

P1236078Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Occipital Lobe

P1236062Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Corpus Callosum

P1236045Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Precentral Gyrus

P1236073Alz 1 mg
EUR 471

Frozen Tissue Section - Alzheimer's Disease: Brain: Amygdala

T1236036Alz 5 slides
EUR 475

Total Protein - Alzheimer's Disease: Brain: Medulla oblongata

P1236057Alz 1 mg
EUR 471

Total Protein - Alzheimer's Disease: Brain: Postcentral Gyrus

P1236072Alz 1 mg
EUR 471

Frozen Tissue Section - Alzheimer's Disease: Brain: Pituitary

T1236068Alz 5 slides
EUR 883

Frozen Tissue Section - Alzheimer's Disease: Brain: Cerebellum

T1236039Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Hippocampus

T1236052Alz 5 slides
EUR 883

Paraffin Tissue Section - Alzheimer's Disease: Brain: Cerebellum

T2236039Alz 5 slides
EUR 238

Genomic DNA - Alzheimer's Disease: Brain, from a single donor

D1236035Alz 50 ug
EUR 489

Frozen Tissue Section - Alzheimer's Disease: Brain: Frontal Lobe

T1236051Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Parietal Lobe

T1236066Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Temporal Lobe

T1236078Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Occipital Lobe

T1236062Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Corpus Callosum

T1236045Alz 5 slides
EUR 475

Total Protein - Parkinson's Disease: Brain: Thalamus

P1236079Par 1 mg
EUR 471

Frozen Tissue Section - Alzheimer's Disease: Brain: Precentral Gyrus

T1236073Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Medulla oblongata

T1236057Alz 5 slides
EUR 475

Frozen Tissue Section - Alzheimer's Disease: Brain: Postcentral Gyrus

T1236072Alz 5 slides
EUR 475

Genomic DNA - Alzheimer's Disease: Brain: Pons, from a single donor

D1236071Alz 50 ug
EUR 489

Paraffin Tissue Section - Alzheimer's Disease: Brain: Medulla oblongata

T2236057Alz 5 slides
EUR 475

Genomic DNA - Alzheimer's Disease: Brain: Cerebellum, from a single donor

D1236039Alz 50 ug
EUR 489

Frozen Tissue Section - Parkinson's Disease: Brain: Thalamus

T1236079Par 5 slides
EUR 475

Genomic DNA - Alzheimer's Disease: Brain: Frontal Lobe, from a single donor

D1236051Alz 50 ug
EUR 489

Total Protein - Multiple Sclerosis Disease: Brain: Thalamus

P1236079Msc 1 mg
EUR 471

Genomic DNA - Alzheimer's Disease: Brain: Parietal Lobe, from a single donor

D1236066Alz 50 ug
EUR 489

Genomic DNA - Alzheimer's Disease: Brain: Temporal Lobe, from a single donor

D1236078Alz 50 ug
EUR 489

Paraffin Tissue Section - Parkinson's Disease: Brain: Thalamus

T2236079Par 5 slides
EUR 238

Genomic DNA - Alzheimer's Disease: Brain: Occipital Lobe, from a single donor

D1236062Alz 50 ug
EUR 489

Genomic DNA - Alzheimer's Disease: Brain: Precentral Gyrus , from a single donor

D1236073Alz 50 ug
EUR 489

Genomic DNA - Alzheimer's Disease: Brain: Corpus Callosum, from a single donor

D1236045Alz 50 ug
EUR 489

Genomic DNA - Alzheimer's Disease: Brain: Postcentral Gyrus , from a single donor

D1236072Alz 50 ug
EUR 489

Genomic DNA - Alzheimer's Disease: Brain: Medulla oblongata, from a single donor

D1236057Alz 50 ug
EUR 489

Frozen Tissue Section - Multiple Sclerosis Disease: Brain: Thalamus

T1236079Msc 5 slides
EUR 475

Paraffin Tissue Section - Multiple Sclerosis Disease: Brain: Thalamus

T2236079Msc 5 slides
EUR 238

Pons (Alzheimer's Disease) Lysate

XBL-10298 0.1 mg
EUR 796.2
Description: Human pons tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human pons tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the pons tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The pons tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Genomic DNA - Parkinson's Disease: Brain: Thalamus, from a single donor

D1236079Par 50 ug
EUR 489

Paraffin Tissue Section - Alzheimers Disease: Brain

T2236035Alz 5 slides
EUR 238

Amygdala (Alzheimer's Disease) Lysate

XBL-10274 0.1 mg
EUR 796.2
Description: Human amygdala tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human amygdala tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the amygdala tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The amygdala tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Total RNA - Alzheimer's Disease: Pons

R1236071Alz-10 10 ug
EUR 421.2

Hippocampus (Alzheimer's Disease) Lysate

XBL-10286 0.1 mg
EUR 922.2
Description: Human hippocamps tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human hippocamps tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the hippocamps tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The hippocamps tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Membrane Protein - Alzheimer's Disease:Brain: Amygdala

P3236036Alz 0.1 mg
EUR 410

Paraffin Tissue Section - Alzheimers Disease: Brain: Pons

T2236071Alz 5 slides
EUR 238

Genomic DNA - Multiple Sclerosis Disease: Brain: Thalamus, from a single donor

D1236079Msc 50 ug
EUR 489

Frontal Lobe (Alzheimer's Disease) Lysate

XBL-10282 0.1 mg
EUR 796.2
Description: Human frontal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human frontal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the frontal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The frontal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Membrane Protein - Alzheimer's Disease:Brain: Hippocampus

P3236052Alz 0.1 mg
EUR 508

Human Alzheimer's Disease Primer Library

HAZD-I 1 set
EUR 657.6

Parietal Lobe (Alzheimer's Disease) Lysate

XBL-10294 0.1 mg
EUR 796.2
Description: Human parietal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human parietal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the parietal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The parietal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Temporal Lobe (Alzheimer's Disease) Lysate

XBL-10314 0.1 mg
EUR 796.2
Description: Human temporal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human temporal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the temporal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The temporal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Occipital lobe (Alzheimer's Disease) Lysate

XBL-10290 0.1 mg
EUR 796.2
Description: Human occipital lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human occipital lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the occipital lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The occipital lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Membrane Protein - Alzheimer's Disease:Brain: Temporal Lobe

P3236078Alz 0.1 mg
EUR 410

Corpus Callosum (Alzheimer's Disease) Lysate

XBL-10278 0.1 mg
EUR 796.2
Description: Human corpus Callosum tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human corpus Callosum tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the corpus Callosum tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The corpus Callosum tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Paraffin Tissue Section - Alzheimers Disease: Brain: Amygdala

T2236036Alz 5 slides
EUR 238

Precentral Gyrus (Alzheimer's Disease) Lysate

XBL-10306 0.1 mg
EUR 796.2
Description: Human precentral gyrus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human precentral gyrus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the precentral gyrus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The precentral gyrus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Amygdala (Alzheimer's Disease) Membrane Lysate

XBL-10272 0.1 mg
EUR 752.1
Description: Human brain amygdala tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human amygdala tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain amygdala tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain amygdala tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Postcentral Gyrus (Alzheimer's Disease) Lysate

XBL-10302 0.1 mg
EUR 796.2
Description: Human postcentral gyrus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human postcentral gyrus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the postcentral gyrus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The postcentral gyrus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Total RNA - Alzheimer's Disease: Frontal Lobe

R1236051Alz-10 10 ug
EUR 421.2

Total RNA - Alzheimer's Disease: Parietal Lobe

R1236066Alz-10 10 ug
EUR 421.2

Total RNA - Alzheimer's Disease: Temporal Lobe

R1236078Alz-10 10 ug
EUR 421.2

Paraffin Tissue Section - Alzheimers Disease: Brain: Hippocampus

T2236052Alz 5 slides
EUR 758

Total RNA - Alzheimer's Disease: Occipital Lobe

R1236062Alz-10 10 ug
EUR 421.2

Paraffin Tissue Section - Alzheimers Disease: Brain: Frontal Lobe

T2236051Alz 5 slides
EUR 238

Hippocampus (Alzheimer's Disease) Membrane Lysate

XBL-10284 0.1 mg
EUR 852.9
Description: Human brain hippocamps tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human hippocamps tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain hippocamps tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain hippocamps tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Total RNA - Alzheimer's Disease: Corpus Callosum

R1236045Alz-10 10 ug
EUR 421.2

Paraffin Tissue Section - Alzheimers Disease: Brain: Parietal Lobe

T2236066Alz 5 slides
EUR 238

Paraffin Tissue Section - Alzheimers Disease: Brain: Temporal Lobe

T2236078Alz 5 slides
EUR 238

Total RNA - Alzheimer's Disease: Precentral Gyrus

R1236073Alz-10 10 ug
EUR 421.2

Paraffin Tissue Section - Alzheimers Disease: Brain: Corpus Callosum

T2236045Alz 5 slides
EUR 238

Paraffin Tissue Section - Alzheimers Disease: Brain: Occipital Lobe

T2236062Alz 5 slides
EUR 238

Total RNA - Alzheimer's Disease: Postcentral Gyrus

R1236072Alz-10 10 ug
EUR 421.2

Hippocampus (Alzheimer's Disease) Cytoplasmic Lysate

XBL-10283 0.1 mg
EUR 273.3
Description: Human brain hippocamps tissue cytoplasmic protein lysate was prepared by isolating the cytoplasmic protein from whole tissue homogenates using a proprietary technique. The human hippocamps tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The cytoplasmic protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, glycerol, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain hippocamps tissue cytoplasmic protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain hippocamps tissue cytoplasmic protein is then Western analyzed by GAPDH antibody, and the expression level is consistent with each lot.

Temporal Lobe (Alzheimer's Disease) Membrane Lysate

XBL-10312 0.1 mg
EUR 752.1
Description: Human brain temporal lobe tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human temporal lobe tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain temporal lobe tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain temporal lobe tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Non-Ab Component of Alzheimer's Disease Amyloid

5-01639 4 x 1mg Ask for price

Non-Ab Component of Alzheimer's Disease Amyloid

SP-89317-1 1 mg
EUR 343.2

Paraffin Tissue Section - Alzheimers Disease: Brain: Precentral Gyrus (Movement)

T2236073Alz 5 slides
EUR 238

Paraffin Tissue Section - Alzheimers Disease: Brain: Postcentral Gyrus (Sensation)

T2236072Alz 5 slides
EUR 238

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue I, 7 different tissues

T6236444Alz 5 slides
EUR 1135

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue II, 7 different tissues

T6236445Alz 5 slides
EUR 1135

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue III, 8 different tissues

T6236446Alz 5 slides
EUR 1135

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue IV, 7 different tissues

T6236564Alz 5 slides
EUR 1135

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue I, 8 different tissues

T8236444Alz 5 slides
EUR 648

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue II, 7 different tissues

T8236445Alz 5 slides
EUR 648

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue IV, 7 different tissues

T8236564Alz 5 slides
EUR 648

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue III, 8 different tissues

T8236446Alz 5 slides
EUR 648

cDNA - Parkinson's Disease: Brain

C1236035Par 40 reactions
EUR 729

Alzheimers Disease gamma-Secretase Detection Set

PSI-1820 1 Set
EUR 752.1
Description: Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The β-amyloid protein precursor (APP) is cleaved by three enzymes (TACE, BACE/BACE2 and γ-secretase) at three distinct sites (α, β and γ respectively). The γ-secretase complex is a membrane-bound aspartyl protease that can cleave certain proteins at peptide bonds buried within the hydrophobic environment of the lipid bilayer and is composed of the proteins APH1, nicastrin, PEN2 and presenilin1. Its cleavage of APP results in either the non-toxic p3 (from the α and γ cleavage site) or the toxic Aβ (from the β and γ cleavage site). APH1 was initially identified as a component of the Notch pathway and exists in at least three distinct isoforms with APH1a as the principal isoform present in the γ-secretase complex. Mice deficient in this isoform, but not the other two, were lethal at E10.5, with impaired vascular and neural development observed. Besides acting as a critical component of the γ-secretase complex, nicastrin is also thought to be involved in cell proliferation and signaling, especially in regards to activation of Notch receptors as loss of nicastrin expression results in mouse embryonic lethality. Presenilin1 was initially identified a marker of susceptibility to early-onset Alzheimer’s disease.;;For images please see PDF data sheet

Alzheimers Disease B-Amyloid Protein Detection Set

PSI-1812 1 Set
EUR 752.1
Description: Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The βamyloid protein precursor (APP) is cleaved by one of two βsecretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for βsecretase to generate the 4 kDa amyloid-β peptide (Aβ), which is deposited in the Alzheimer’s disease patients’ brains. BACE was identified by several groups independently and designated β-site APP cleaving enzyme (BACE) . BACE is a transmembrane aspartic protease and co-localizes with APP. BACE2 also cleaves APP at β-site and at a different site within Aβ. BACE2 locates on chromosome 21q22.3, the so-called ‘Down critical region’, suggesting that BACE2 and Aβ may also contribute to the pathogenesis of Down syndrome.;;For images please see PDF data sheet

Total Protein - Dementia: Brain: Thalamus

P1236079Dem 1 mg
EUR 471

cDNA - Multiple Sclerosis Disease: Brain

C1236035Msc 40 reactions
EUR 729

Total Protein - Depression: Brain: Thalamus

P1236079Dep 1 mg
EUR 471

cDNA - Parkinson's Disease: Brain: Hippocampus

C1236052Par 40 reactions
EUR 886

Human Brain Thalamus Lysate Membrane Fraction

IHUBRTHLTLM100UG each
EUR 870
Description: Human Brain Thalamus Lysate Membrane Fraction

Frozen Tissue Section - Dementia: Brain: Thalamus

T1236079Dem 5 slides
EUR 475

Frozen Tissue Section - Depression: Brain: Thalamus

T1236079Dep 5 slides
EUR 475

Paraffin Tissue Section - Dementia: Brain: Thalamus

T2236079Dem 5 slides
EUR 238

Paraffin Tissue Section - Depression: Brain: Thalamus

T2236079Dep 5 slides
EUR 238

cDNA - Multiple Sclerosis Disease: Brain: Hippocampus

C1236052Msc 40 reactions
EUR 886

Total RNA - Human Adult Normal Tissue: Brain: Thalamus

R1234079-50 50 ug
EUR 170

Total Protein - Human Adult Normal Tissue: Brain: Thalamus

P1234079 1 mg
EUR 188

Frozen Tissue Section - Human Adult Normal: Brain: Thalamus

T1234079 5 slides
EUR 343

Membrane Protein - Human Adult Normal Tissue: Brain: Thalamus

P3234079 0.1 mg
EUR 270

Paraffin Tissue Section - Human Adult Normal: Brain: Thalamus

T2234079 5 slides
EUR 185

Genomic DNA - Dementia: Brain: Thalamus, from a single donor

D1236079Dem 50 ug
EUR 489

Genomic DNA - Depression: Brain: Thalamus, from a single donor

D1236079Dep 50 ug
EUR 489

Thalamus

PC35127 Thalamus
EUR 475.2

cDNA - Human Diabetic Diseased Tissue: Brain

C1236035Dia 40 reactions
EUR 729

Single Donor Human Alzheimer's Serum

ISERSALZ each
EUR 209
Description: Single Donor Human Alzheimer's Serum

Single Donor Human Alzheimer's Plasma

IPLASALZ each
EUR 209
Description: Single Donor Human Alzheimer's Plasma

Thalamus Membrane Lysate

XBL-10204 0.1 mg
EUR 619.8
Description: Human brain thalamus tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human thalamus tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain thalamus tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain thalamus tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Human Thalamus Tissue Lysate

30R-AT053 150 ug
EUR 282
Description: Fresh tissue lysate isolated from the thalamus of human brain

Total Protein - Parkinson's Disease: Brain

P1236035Par 1 mg
EUR 471

cDNA - Congenital heart disease: Heart

C1236122Hd-3 40 reactions
EUR 729

Total Protein - Parkinson's Disease: Brain: Pons

P1236071Par 1 mg
EUR 471

Frozen Tissue Section - Parkinson's Disease: Brain

T1236035Par 5 slides
EUR 475

Total Protein - Multiple Sclerosis Disease: Brain

P1236035Msc 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Amygdala

P1236036Par 1 mg
EUR 471

Paraffin Tissue Section - Parkinson's Disease: Brain

T2236035Par 5 slides
EUR 238

Total Protein - Parkinson's Disease: Brain: Cerebellum

P1236039Par 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Frontal Lobe

P1236051Par 1 mg
EUR 471

Frozen Tissue Section - Parkinson's Disease: Brain: Pons

T1236071Par 5 slides
EUR 475

Total Protein - Parkinson's Disease: Brain: Parietal Lobe

P1236066Par 1 mg
EUR 471

Total Protein - Multiple Sclerosis Disease: Brain: Pons

P1236071Msc 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Temporal Lobe

P1236078Par 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Occipital Lobe

P1236062Par 1 mg
EUR 471

Paraffin Tissue Section - Parkinson's Disease: Brain: Pons

T2236071Par 5 slides
EUR 238

Total Protein - Parkinson's Disease: Brain: Corpus Callosum

P1236045Par 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Precentral Gyrus

P1236073Par 1 mg
EUR 471

Frozen Tissue Section - Multiple Sclerosis Disease: Brain

T1236035Msc 5 slides
EUR 475

Frozen Tissue Section - Parkinson's Disease: Brain: Amygdala

T1236036Par 5 slides
EUR 475

Total Protein - Multiple Sclerosis Disease: Brain: Amygdala

P1236036Msc 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Medulla oblongata

P1236057Par 1 mg
EUR 471

Total Protein - Parkinson's Disease: Brain: Postcentral Gyrus

P1236072Par 1 mg
EUR 471

Frozen Tissue Section - Parkinson's Disease: Brain: Pituitary

T1236068Par 5 slides
EUR 883

Frozen Tissue Section - Parkinson's Disease: Brain: Cerebellum

T1236039Par 5 slides
EUR 475

Paraffin Tissue Section - Multiple Sclerosis Disease: Brain

T2236035Msc 5 slides
EUR 238

This review covers the mechanistic action photobiomodulation therapies against Alzheimer’s disease at the cellular level. Safe and effective dose has been found in animal models, and the first human case studies have given reasons for doing large scale clinical trials. A brief discussion on the minimum effective dose tolerated and the maximum conclude this review, and provide the basis for a successful translation from bench to bedside.